Anzeige
Mehr »
Montag, 20.10.2025 - Börsentäglich über 12.000 News
Homeland Uranium: Vom Geheimtipp zum potenziellen Entwicklerstar
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4HE | ISIN: US29415J1060 | Ticker-Symbol: 5HJ
Tradegate
20.10.25 | 08:01
0,650 Euro
+1,56 % +0,010
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ENVVENO MEDICAL CORPORATION Chart 1 Jahr
5-Tage-Chart
ENVVENO MEDICAL CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
0,6450,67011:14
0,6450,67010:05

Aktuelle News zur ENVVENO MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.10.EnVVeno Medical: NASDAQ-Notierung wegen Unterschreitung des Mindestkurses gefährdet-
10.10.enVVeno Medical Corp - 8-K, Current Report1
26.09.enVVeno Medical Corporation: enVVeno Medical Participates in Virtual Investor "What This Means" Segment264Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of...
► Artikel lesen
15.09.enVVeno Medical to appeal FDA's not-approvable letter for VenoValve5
15.09.enVVeno Medical Corporation: enVVeno Medical Updates Regulatory Status of VenoValve230IRVINE, CA / ACCESS Newswire / September 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease...
► Artikel lesen
25.08.NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve16
20.08.FDA denies PMA submission for enVVeno Medical's VenoValve11
ENVVENO MEDICAL Aktie jetzt für 0€ handeln
20.08.XFRA 5HJ: WIEDERAUFNAHME/RESUMPTION289FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
20.08.enVVeno Medical stock plummets after FDA rejects VenoValve approval14
20.08.FDA verweigert Zulassung für VenoValve: Aktie von enVVeno Medical stürzt um 70 % ab12
20.08.Rückschlag für enVVeno Medical: FDA verweigert Zulassung für Venenklappe VenoValve15
20.08.FDA rejects enVVeno Medical's VenoValve for chronic venous insufficiency4
20.08.enVVeno Medical Corp - 8-K, Current Report6
20.08.XFRA 5HJ: AUSSETZUNG/SUSPENSION383DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILENVVENO MEDICAL...
► Artikel lesen
20.08.enVVeno Medical Corporation: enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve615IRVINE, CA / ACCESS Newswire / August 20, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease...
► Artikel lesen
15.08.enVVeno Medical Corporation: enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech336- Live webcast on Thursday, August 21stat 2:00 PM ET IRVINE, CA / ACCESS Newswire / August 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards...
► Artikel lesen
06.08.enVVeno Medical's VenoValve shows cost-effectiveness for CVI treatment3
06.08.enVVeno Medical Corporation: Health Economic Study Shows That enVVeno Medical's VenoValve Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency302Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatmentsThe VenoValve could...
► Artikel lesen
04.08.enVVeno Medical Corporation: enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company255- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency- FDA decision expected...
► Artikel lesen
01.08.enVVeno Medical reports Q2 results1
Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1